Strategic partnerships Mytos is actively expanding its collaborative network with leading biotech players (Aspen, StemSight, Rinri Therapeutics, Novadip, Pluristyx) to scale automated manufacturing of regenerative cell therapies, indicating strong outbound collaboration opportunities with CDMOs, biomanufacturing consortia, and clinical developers.

Scale for patients With a vision to produce stem cell derived therapies at scale and moving toward patient-ready products by 2027, there is a sales opening for platforms, consumables, and services that enable high‑throughput, GMP‑compliant automated manufacturing and supply chain integration.

Automation backbone Mytos relies on its iDEM robotics platform and automation for diverse cell programs, presenting cross‑sell potential for robotics integration, software tooling, data analytics, process control, and maintenance services to institutions building or upgrading automated GMP facilities.

Funding momentum With over $39M raised and strategic VC backing from notable investors, Mytos is well positioned to pursue rapid partnership expansion, pilot programs, and joint development agreements with biotech sponsors seeking scalable manufacturing capabilities.

Talent and culture A team of engineers from industry leaders and a scientific foundation signal readiness to adopt and integrate advanced manufacturing tech; possible sales angles include professional services, training, and collaboration on knowledge transfer for new adopters of automated cell production.